VT H0676The bill aims to ensure that patients can continue to access thyroid medications that are derived from animals. This is particularly important for individuals who rely on these specific treatments for their health needs. The legislation seeks to protect the availability of these medications in Vermont.
VT H0676 is a house bill in the Vermont 2025-2026 Session, sponsored by Gregory Burtt (R), currently “Introduced” since January 14, 2026.
We track 1,717 Vermont bills this session, 18 of them sponsored by Gregory Burtt.
Supporters of the bill would highlight its importance in preserving essential treatment options for patients who benefit from animal-derived thyroid medications. They may argue that maintaining access to these medications is crucial for patient health and well-being, emphasizing the need for diverse treatment options in healthcare.
Critics of the bill may argue that it could hinder progress towards more modern, synthetic alternatives for thyroid treatment. They might express concerns that focusing on animal-derived medications could limit research and development of new therapies, potentially impacting long-term patient care and innovation in the pharmaceutical industry.
About This Analysis
This summary was generated using AI from the bill's official text and metadata. Data sourced from LegiScan and the Vermont General Assembly. Conflict-of-interest analysis for this bill is coming soon.
What does VT H0676 do?
The bill aims to ensure that patients can continue to access thyroid medications that are derived from animals. This is particularly important for individuals who rely on these specific treatments for their health needs. The legislation seeks to protect the availability of these medications in Vermont.
What is the status of VT H0676?
VT H0676 is currently “Introduced” in the Vermont legislature.
Who sponsored VT H0676?
Gregory Burtt (R) sponsored VT H0676.
